Kiniksa Records Record Performance Following ARCALYST Launch and Raises Guidance
KNSA Kiniksa Pharmaceuticals International Plc
$93.54 -1.59%
View chart & analysis → - 1Kiniksa's diluted GAAP earnings per share of $0.56 exceeded the consensus EPS of $0.32.
- 2Kiniksa's earnings grew, recording a 75.0% beat against consensus.
- 3Management raised the 2026 guidance for ARCALYST.
So what's the key point?
Kiniksa earned $0.56 per share, which was higher than what experts expected. Management also raised the 2026 outlook for ARCALYST.
Source Earnings Whispers · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.